Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

GSK publishes Annual Report 2024

27th Feb 2025 10:00

RNS Number : 7142Y
GSK PLC
27 February 2025
 

 

GSK plc

(the 'Company')

 

Publication of Annual Report 2024

 

 

The Company has today published on its website www.annualreport.gsk.com its Annual Report for the year ended 31 December 2024 ('Annual Report 2024').

 

In compliance with Listing Rule 6.4.1R of the UK Financial Conduct Authority ('FCA'), the Annual Report 2024 has been submitted to the FCA's National Storage Mechanism ('NSM') and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

A hard copy version of the Annual Report 2024 and the Notice of Annual General Meeting 2025 ('AGM Notice') will be sent to those shareholders who have elected to receive paper communications on or around 24 March 2025. The AGM Notice will be made available to shareholders who have not elected to receive paper communications on the same date.

 

This announcement is not a substitute for reading the Annual Report 2024 in full.

 

Additional Information

 

For the purposes of complying with the FCA's Disclosure Guidance and Transparency Rules ('DTRs') and the requirements imposed on issuers through the DTRs, information required to be communicated with the media in unedited full text was included in the Annual Report 2024. The Annual Report 2024 was submitted to the NSM and will shortly be available for inspection. It is also available on the Company's website as noted above.

 

This announcement is made in accordance with DTR 6.3.5R(1A).

 

V A Whyte

Company Secretary

 

27 February 2025

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSEANAXASSSEEA

Related Shares:

Glaxosmithkline
FTSE 100 Latest
Value8,632.33
Change89.77